Supernus Pharmaceuticals Net Income 2011-2025 | SUPN

Supernus Pharmaceuticals net income from 2011 to 2025. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Supernus Pharmaceuticals Annual Net Income
(Millions of US $)
2024 $74
2023 $1
2022 $64
2021 $53
2020 $127
2019 $113
2018 $111
2017 $57
2016 $91
2015 $14
2014 $-11
2013 $-92
2012 $-47
2011 $50
2010 $-42
Supernus Pharmaceuticals Quarterly Net Income
(Millions of US $)
2025-03-31 $-12
2024-12-31 $15
2024-09-30 $38
2024-06-30 $20
2024-03-31 $0
2023-12-31 $1
2023-09-30 $-16
2023-06-30 $-1
2023-03-31 $17
2022-12-31 $29
2022-09-30 $2
2022-06-30 $8
2022-03-31 $26
2021-12-31 $2
2021-09-30 $22
2021-06-30 $24
2021-03-31 $6
2020-12-31 $31
2020-09-30 $40
2020-06-30 $35
2020-03-31 $22
2019-12-31 $33
2019-09-30 $29
2019-06-30 $33
2019-03-31 $18
2018-12-31 $26
2018-09-30 $28
2018-06-30 $31
2018-03-31 $26
2017-12-31 $14
2017-09-30 $16
2017-06-30 $17
2017-03-31 $10
2016-12-31 $14
2016-09-30 $62
2016-06-30 $10
2016-03-31 $5
2015-12-31 $7
2015-09-30 $4
2015-06-30 $2
2015-03-31 $1
2014-12-31 $4
2014-09-30 $-2
2014-06-30 $3
2014-03-31 $-16
2013-12-31 $-22
2013-09-30 $-24
2013-06-30 $-27
2013-03-31 $-18
2012-12-31 $-14
2012-09-30 $-13
2012-06-30 $-10
2012-03-31 $-10
2011-12-31 $82
2011-09-30 $-11
2011-06-30 $-8
2011-03-31 $-12
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.800B $0.662B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.579B 7.44
Dr Reddy's Laboratories (RDY) India $12.154B 22.06
BridgeBio Pharma (BBIO) United States $6.126B 0.00
Bausch Health Cos (BHC) Canada $1.658B 1.21
Amphastar Pharmaceuticals (AMPH) United States $1.200B 7.99
Taysha Gene Therapies (TSHA) United States $0.524B 0.00
Personalis (PSNL) United States $0.415B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00